AP NEWS

The Global Market for Travel Vaccines (2018-2022) with GlaxoSmithKline, Pfizer, Sanofi and Valneva Dominating - ResearchAndMarkets.com

January 3, 2019

DUBLIN--(BUSINESS WIRE)--Jan 3, 2019--The “Global Travel Vaccines Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The travel vaccines market will register a CAGR of almost 10% by 2022.

Increased incidence of travel-related diseases is expected to drive the market growth

Traveling is often associated with higher health risks especially regarding infectious diseases. Thus, the rising incidence of travel related diseases will lead to more investments in the global travel vaccines market for the development of more effective vaccines.

Increase in global travel and migration

With the rise in traveling over the past few years has resulted in the spread of pathogens and disease-causing vectors worldwide. The increase in travel and migration offers huge opportunities to the manufacturers to invest in the R&D of new and more effective vaccines.

High cost of travel vaccinations

Travel clinics offer vaccinations at a slightly higher price and new vaccines are usually more expensive.

Key Players

GlaxoSmithKline Pfizer Sanofi Valneva

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

Market definition Market sizing 2017 Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

PART 08: MARKET SEGMENTATION BY TARGET DISEASE FOR IMMUNIZATION

Segmentation by target disease for immunization Comparison by target disease for immunization Influenza - Market size and forecast 2017-2022 Diphtheria - Market size and forecast 2017-2022 Others - Market size and forecast 2017-2022 Hepatitis - Market size and forecast 2017-2022 Typhoid - Market size and forecast 2017-2022 Polio - Market size and forecast 2017-2022 Yellow fever - Market size and forecast 2017-2022 Market opportunity by target disease

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

PART 13: MARKET TRENDS

Changes in the demographic profile of travelers globally Increased incidence of travel-related diseases Initiatives by governments and other organizations to ensure travel safety Evolving epidemiological patterns of infectious diseases in different countries

PART 14: VENDOR LANDSCAPE

Overview Landscape disruption

PART 15: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors GlaxoSmithKline Pfizer Sanofi Valneva

For more information about this report visit https://www.researchandmarkets.com/research/q5xj77/the_global_market?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190103005320/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Vaccines

KEYWORD:

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/03/2019 06:46 AM/DISC: 01/03/2019 06:45 AM

http://www.businesswire.com/news/home/20190103005320/en

AP RADIO
Update hourly